Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Finek, J. [1 ,2 ]
Poprach, A. [3 ,4 ]
Melichar, B. [5 ,6 ]
Kopecky, J. [7 ,8 ]
Zemanova, M. [7 ,8 ]
Buchler, T. [7 ,9 ]
Kopeckova, K. [10 ,11 ]
Mlcoch, T. [12 ]
Dolezal, T. [4 ,13 ]
Fiala, O. [1 ,2 ]
机构：
[1] Charles Univ Prague, Teaching Hosp Pilsen, Dept Radiotherapy & Oncol, Plzen, Czech Republic
[2] Charles Univ Prague, Fac Med Pilsen, Plzen, Czech Republic
[3] Masaryk Univ, Masaryk Mem Canc Inst, Clin Comprehens Canc Care, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Brno, Czech Republic
[5] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic
[6] Univ Hosp, Olomouc, Czech Republic
[7] Charles Univ Prague, Fac Med 1, Oncol, Prague, Czech Republic
[8] Gen Univ Hosp, Prague, Czech Republic
[9] Thomayer Hosp, Prague, Czech Republic
[10] Univ Hosp Motol, Dept Oncol, Prague, Czech Republic
[11] Charles Univ Prague, Fac Med 2, Prague, Czech Republic
[12] Inst Hlth Econ & Technol Assessment, HTA Dept, Prague, Czech Republic
[13] Masaryk Univ, Inst Hlth Econ & Technol Assessment, Dept Pharmacol, Prague, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
957P
引用
收藏
页码：387 / 387
页数：1
相关论文
共 50 条
  • [41] Cost per month of overall survival and progression-free survival: everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma
    Swallow, Elyse
    Ghate, Sameer
    Messali, Andrew
    Mcdonald, Evangeline
    Duchesneau, Emilie
    Perez, Jose R.
    BJU INTERNATIONAL, 2016, 118 : 17 - 18
  • [42] Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
    McAlister, Renee K.
    Aston, Jonathan
    Pollack, Megan
    Du, Liping
    Koyama, Tatsuki
    Chism, David D.
    ONCOLOGIST, 2018, 23 (06): : 686 - 692
  • [43] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [44] PROGRESSION-FREE SURVIVAL (PFS) MODELING OF FIRST-LINE METASTATIC RENAL CELL CARCINOMA (1L MRCC) USING TUMOR GROWTH INHIBITION (TGI) METRICS.
    Li, J.
    Lin, S.
    Shahin, M.
    Nickens, D.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S71 - S71
  • [45] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [46] The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma
    Ishihara, Hiroki
    Kondo, Tsunenori
    Omae, Kenji
    Takagi, Toshio
    Izuka, Jumpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (06) : 568 - 574
  • [47] Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
    van der Veldt, Astrid A. M.
    Eechoute, Karel
    Gelderblom, Hans
    Gietema, Jourik
    Guchelaar, Henk-Jan
    van Erp, Nielka P.
    van den Eertwegh, Alfons J. M.
    Haanen, John B.
    Mathijssen, Ron H. J.
    Wessels, Judith A. M.
    CLINICAL CANCER RESEARCH, 2011, 17 (03) : 620 - 629
  • [48] Bevacizumab as first-line therapy in metastatic renal cell carcinoma. Progression-free survival for 3 years
    Pichler, R.
    Horninger, W.
    Aigner, F.
    Heidegger, I.
    UROLOGE, 2016, 55 (03): : 381 - 385
  • [49] The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Keizman, Daniel
    Ish-Shalom, Maya
    Huang, Peng
    Eisenberger, Mario A.
    Pili, Roberto
    Hammers, Hans
    Carducci, Michael A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 202 - 208
  • [50] Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).
    Tannir, Nizar M.
    Figlin, Robert A.
    Gore, Martin Eric
    Michaelson, Dror
    Motzer, Robert J.
    Porta, Camillo
    Rini, Brian I.
    Hoang, Caroline J.
    Lin, Xun
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345